Journal of Thrombosis and Thrombolysis

, Volume 35, Issue 3, pp 346–351

Pathophysiology and management of thrombosis in cancer: 150 years of progress


DOI: 10.1007/s11239-013-0897-9

Cite this article as:
Soff, G.A. J Thromb Thrombolysis (2013) 35: 346. doi:10.1007/s11239-013-0897-9


The association of thrombosis with cancer has been recognized since the middle of the nineteenth century. It remains a common and serious complication of the cancer itself, as well as chemotherapy. Thrombosis is the second leading cause of death in cancer patients, second only to the cancer itself. For many years the treatment options for managing thrombosis in cancer had been static, but the past decade has seen significant evolution in the management, with the clear superiority of low molecular weight heparin over warfarin for secondary prevention of thrombosis. This article will review the understanding and management of thrombosis in cancer.



Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Hematologic Oncology, Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Weill Cornell College of MedicineNew YorkUSA